Tower Research Capital (TRC)’s Five Prime Therapeutics, Inc. FPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-3,426
| Closed | -$129K | – | 6313 |
|
|
2021
Q1 | $129K | Buy |
3,426
+1,888
| +123% | +$47.1K | ﹤0.01% | 2381 |
|
|
2020
Q4 | $26K | Sell |
1,538
-32,907
| -96% | -$412K | ﹤0.01% | 3710 |
|
|
2020
Q3 | $162K | Buy |
34,445
+26,610
| +340% | +$135K | ﹤0.01% | 2762 |
|
|
2020
Q2 | $48K | Buy |
+7,835
| New | +$32.3K | ﹤0.01% | 3092 |
|
|
2019
Q4 | – | Sell |
-6,557
| Closed | -$25K | – | 4761 |
|
|
2019
Q3 | $25K | Buy |
6,557
+1,183
| +22% | +$6.49K | ﹤0.01% | 2323 |
|
|
2019
Q2 | $33K | Buy |
5,374
+5,074
| +1,691% | +$48.5K | ﹤0.01% | 1848 |
|
|
2019
Q1 | $4K | Buy |
+300
| New | +$3.42K | ﹤0.01% | 3235 |
|
|
2018
Q4 | – | Sell |
-296
| Closed | -$4K | – | 4604 |
|
|
2018
Q3 | $4K | Buy |
296
+228
| +335% | +$3.39K | ﹤0.01% | 3252 |
|
|
2018
Q2 | $1K | Sell |
68
-1,744
| -96% | -$30.4K | ﹤0.01% | 3553 |
|
|
2018
Q1 | $31K | Buy |
1,812
+68
| +4% | +$1.33K | ﹤0.01% | 1960 |
|
|
2017
Q4 | $38K | Buy |
1,744
+1,533
| +727% | +$49.3K | ﹤0.01% | 1550 |
|
|
2017
Q3 | $9K | Buy |
211
+111
| +111% | +$3.48K | ﹤0.01% | 3131 |
|
|
2017
Q2 | $3K | Buy |
+100
| New | +$3.12K | ﹤0.01% | 2268 |
|
|
2017
Q1 | – | Sell |
-1,123
| Closed | -$56K | – | 4242 |
|
|
2016
Q4 | $56K | Buy |
1,123
+1,073
| +2,146% | +$56.4K | 0.01% | 1367 |
|
|
2016
Q3 | $3K | Buy |
+50
| New | +$2.39K | ﹤0.01% | 2944 |
|
|
2016
Q2 | – | Sell |
-114
| Closed | -$5K | – | 5224 |
|
|
2016
Q1 | $5K | Buy |
+114
| New | +$3.92K | ﹤0.01% | 2783 |
|
|
2015
Q4 | – | Sell |
-1,364
| Closed | -$21K | – | 5300 |
|
|
2015
Q3 | $21K | Buy |
1,364
+862
| +172% | +$18.5K | ﹤0.01% | 1703 |
|
|
2015
Q2 | $12K | Sell |
502
-3,278
| -87% | -$73K | ﹤0.01% | 2562 |
|
|
2015
Q1 | $87K | Buy |
3,780
+2,956
| +359% | +$74.6K | 0.01% | 1009 |
|
|
2014
Q4 | $22K | Buy |
824
+443
| +116% | +$7.63K | ﹤0.01% | 1537 |
|
|
2014
Q3 | $4K | Sell |
381
-2,987
| -89% | -$37.7K | ﹤0.01% | 3496 |
|
|
2014
Q2 | $52K | Buy |
3,368
+3,308
| +5,513% | +$47.4K | 0.01% | 1274 |
|
|
2014
Q1 | $1K | Buy |
+60
| New | +$1.02K | ﹤0.01% | 4252 |
|
Tower Research Capital (TRC)'s FPRX Position: Q2 2021 in Review
Tower Research Capital (TRC) sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 3,426 shares — an estimated $129K sold.
Tower Research Capital (TRC) first reported a position in FPRX in Q1 2014 and held it in 23 quarters. The position peaked at $162K in Q3 2020. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.
- Tower Research Capital (TRC) reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
- Tower Research Capital (TRC) sold 3,426 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $129K.
- Tower Research Capital (TRC) first reported a position in Five Prime Therapeutics, Inc. in Q1 2014 and held it in 23 quarters.
- Tower Research Capital (TRC)'s Five Prime Therapeutics, Inc. position peaked at $162K in Q3 2020.
- 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.
Based on Tower Research Capital (TRC)'s 13F filing for Q2 2021, filed 16 Aug 2021.